Daxor (NASDAQ:DXR) versus Chemed (NYSE:CHE) Financial Analysis

Daxor (NASDAQ:DXR) and Chemed (NYSE:CHE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Earnings & Valuation

This table compares Daxor and Chemed”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Chemed	$2.43 billion	2.64	$302.00 million	$19.45	22.63

Chemed has higher revenue and earnings than Daxor.

Institutional & Insider Ownership

1.3% of Daxor shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 59.5% of Daxor shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Daxor and Chemed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0	0	1	0	3.00
Chemed	0	0	4	0	3.00

Daxor currently has a consensus target price of $25.00, indicating a potential upside of 84.09%. Chemed has a consensus target price of $578.50, indicating a potential upside of 31.46%. Given Daxor’s higher possible upside, analysts plainly believe Daxor is more favorable than Chemed.

Profitability

This table compares Daxor and Chemed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Chemed	11.56%	25.83%	17.77%

Volatility and Risk

Daxor has a beta of -0.07, indicating that its stock price is 107% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Summary

Chemed beats Daxor on 7 of the 9 factors compared between the two stocks.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.